Biosynth Strengthens Position in Peptide Field through Pepceuticals Acquisition

Published on: 

Biosynth has further strengthened its peptide division with the acquisition of Pepceuticals.

Swiss headquartered critical materials supplier, Biosynth, has announced its acquisition of a British manufacturer of synthetic peptides, Pepceuticals, in a Sep. 25, 2023 press release, bolstering its position within the peptide market.

Through this acquisition, Biosynth will gain Pepceuticals’ multi-kilogram good manufacturing practice (GMP) facilities and fill/finish capabilities. With these added offerings, Biosynth will be able to support all phases of the peptide product life cycle and hence assist their customers from clinical trials all the way through to commercialization.

“We are very excited for Pepceuticals to be joining Biosynth,” said Urs Spitz, CEO and president of Biosynth, in the press release. “The Pepceuticals team has great expertise in optimizing the production of peptides and working at GMP and larger scales, making it a natural fit for Biosynth as we round out our peptide offering.”

“The acquisition of Pepceuticals into the Biosynth family strengthens our position in the peptide field,” added Ehab Alramahy, senior vice-president, head of Peptide Division, in the press release. “As we've built the peptide division, our goal has always been to offer a seamless, comprehensive service to our customers. The acquisition represents an important step which allows us to extend our support to clinical trials and commercial supply.”


“Joining the Biosynth Group marks the start of an exciting chapter for our team,” stated Kamal Badiani, managing director of Pepceuticals, in the press release. “We look forward to working together, combining our expertise, and enhancing our offering to our customers. We are excited to join Biosynth and provide leading peptide manufacturing services.”

This latest addition to Biosynth’s peptide division reflects the company’s rapid reaction to an increasing market demand for peptide therapeutics across research, development, and commercial supply. In 2022, the company acquired vivitide and Pepscan, strengthening its peptide manufacturing services and catalog products, and then, in 2023, it added further peptide expertise through the acquisition of Cambridge Research Biochemicals.

Source: Biosynth